SHINE 2Europe partner in a new Horizon project that will involve 720 patients with liver cancer

Liver cancer is the fifth most frequent worldwide and the second most deadly, with about 750,000 cases per year. In addition, liver cancer has a high chance of recurrence, even after surgery. The prevalence of local recurrence after resection of hepatocellular carcinoma is 20% or more. But is it possible that an additional innovative technique during surgery could improve these people’s chances? This is what will be tested in this new international project.

SHINE 2Europe is a partner in LIVERATION, an innovative project funded by the Horizon Europe program and led by the Institut Hospital del Mar with the involvement of  7 other partners. The main objective of this project is to evaluate the effectiveness of Additional Coagulation of the Margin (ACM) in real-life scenarios after liver surgery. Its ultimate goal is to reduce the probability of liver cancer recurrence by conducting a clinical trial in 6 countries, involving 720 patients.

In LIVERATION, SHINE will be delivering the Social Innovation framework and ethical dialogue sessions, leading the social, health and economic assessment, as well as the tasks regarding information and public engagement. It will also be involved in dissemination and communication activities, as well as liaison with other European Union initiatives.

On the 29th and 30th of June, Barcelona hosted the kick-off meeting of this project entitled “Unravelling the Impact of Radiofrequency in Liver Surgery: The Key to Decrease Local Recurrence?” and which will develop over the next 5 years. During the meeting the partners engaged in fruitful discussions about the project overview and conducted an in-depth review of the plan for each work package. This collaborative effort was essential to align SHINE’s activities with those of the other partners and ensure that all details are incorporated into the study protocol.

SHINE is very excited about the journey on this challenging project, joining efforts with the partners to make a significant impact in the field of liver surgery and improve patient outcomes.